CINV Guideline — Part 4: Assessment Tools, Non-Pharmacological Interventions, and Guideline Implementation

Patient Assessment and Monitoring

Systematic assessment of nausea and vomiting is essential for evaluating the efficacy of antiemetic prophylaxis, detecting breakthrough CINV, and guiding treatment modifications. Assessment should occur at each clinical encounter during and after chemotherapy and should document the presence, severity, timing, and impact of nausea and vomiting separately, as these are distinct symptoms that may not correlate with one another.¹

Key Assessment Elements

Standardized Grading and Assessment Tools

CTCAE Grading of Nausea and Vomiting

The Common Terminology Criteria for Adverse Events (CTCAE) provides standardized grading scales for nausea and vomiting that are used universally in clinical trials and clinical practice for toxicity reporting.²

CTCAE v5.0 — Nausea

CTCAE v5.0 — Vomiting

MASCC Antiemesis Tool (MAT)

The MASCC Antiemesis Tool is an 8-item validated patient self-report instrument designed to assess the incidence and severity of acute and delayed nausea and vomiting following chemotherapy. It is the most widely used tool in antiemetic research and is recommended for clinical practice by multiple guideline bodies.³

MAT Structure

The MAT assesses four domains across two time periods:

Endpoints derived from the MAT:

• Complete response (CR): No vomiting and no use of rescue antiemetics in the specified time period
• Complete control (CC): No vomiting, no rescue antiemetics, and nausea rated no more than mild (≤2 on 0–10 scale)
• Total control (TC): No vomiting, no rescue antiemetics, and no nausea (0 on 0–10 scale)

These endpoints are used in clinical trials and quality improvement assessments:

Functional Living Index — Emesis (FLIE)

The FLIE is a validated 18-item quality-of-life instrument specific to CINV. It assesses the impact of nausea and vomiting on daily functioning in two domains (nausea impact and vomiting impact) over a 5-day period. Each item is scored on a 1–7 visual analog scale, yielding a total score of 18–126, where higher scores indicate less impact on daily life. A score >108 (domain score >54) is considered “no impact on daily life.”⁴

Numeric Rating Scale (NRS) for Nausea

A simple 0–10 numeric rating scale where:

This scale is practical for routine clinical use and can be administered at each contact. It should be assessed at minimum once daily during the first 5 days following chemotherapy.

Non-Pharmacological Interventions

Non-pharmacological interventions should be considered as adjuncts to guideline-concordant pharmacological antiemetic prophylaxis. They are particularly important for anticipatory CINV, which responds poorly to pharmacological agents alone, and for patients with refractory symptoms.⁵⁶

Interventions with Established Evidence

Acupuncture and Acupressure

• Mechanism: Stimulation of the P6 (Neiguan) acupoint on the volar aspect of the wrist is hypothesized to modulate vagal afferents and central neurotransmitter pathways
• Evidence: Multiple randomized controlled trials and meta-analyses have demonstrated that P6 acupoint stimulation (via manual acupressure, acupressure wristbands, or electroacupuncture) reduces CINV when used as an adjunct to standard antiemetics. Effect sizes are generally modest.⁷
• Practical application: Acupressure wristbands (e.g., Sea-Band) are non-invasive, inexpensive, and free of adverse effects. They may be applied bilaterally to the P6 point before and during chemotherapy.
• Recommendation: Reasonable adjunctive intervention for interested patients. Should not replace standard antiemetic prophylaxis.

Ginger (Zingiber officinale)

• Mechanism: Anti-emetic properties attributed to gingerols and shogaols, which may antagonize 5-HT3 receptors and exert prokinetic effects
• Evidence: Mixed results from clinical trials. Some studies demonstrate benefit for acute nausea when ginger (250 mg four times daily or 500 mg twice daily) is added to standard antiemetics; others show no significant advantage over placebo.⁸
• Dosing studied: 0.5 to 2 g of ginger extract daily in divided doses, starting 3 days before chemotherapy and continuing for 6 days
• Safety: Generally well tolerated. Rare: heartburn, bruising (theoretical antiplatelet effects at high doses). Potential interaction with anticoagulants — use with caution.
• Recommendation: May be considered as an adjunct for patients who are interested. Not a substitute for standard antiemetic therapy.

Progressive Muscle Relaxation (PMR)

• Evidence: Randomized trials have demonstrated that PMR, when taught before chemotherapy and practiced before and during treatment, reduces the severity of nausea and anxiety in cancer patients receiving chemotherapy.⁹
• Technique: Systematic tensing and relaxing of muscle groups, typically guided by audio recording or trained practitioner
• Recommendation: Recommended as an adjunctive technique, particularly for patients with anxiety-associated nausea

Guided Imagery and Hypnosis

• Evidence: Clinical hypnosis and guided imagery have shown benefit in reducing anticipatory and acute nausea, particularly in pediatric patients. Limited but supportive evidence in adults.¹⁰
• Practical application: Requires access to trained hypnotherapists or validated audio programs
• Recommendation: Particularly useful for anticipatory CINV and in pediatric populations

Cognitive Behavioral Therapy (CBT)

• Evidence: Systematic desensitization and other CBT techniques have demonstrated efficacy for anticipatory CINV. CBT addresses the conditioned response that underlies anticipatory symptoms.
• Recommendation: Recommended for patients with established anticipatory CINV, ideally with referral to a psycho-oncology professional

Interventions with Limited or Mixed Evidence

Dietary and Lifestyle Guidance for Patients

The following practical advice should be provided to all patients receiving emetogenic chemotherapy:

1. Eat small, frequent meals rather than large meals
2. Avoid fatty, greasy, fried, or heavily spiced foods during the period of highest nausea risk
3. Choose bland, dry foods (crackers, toast, rice) when nauseated
4. Cold or room-temperature foods may be better tolerated than hot foods (which produce more odor)
5. Stay well hydrated with clear fluids; sip slowly throughout the day
6. Avoid lying flat immediately after eating; remain upright for at least 30 minutes
7. Avoid strong odors (cooking smells, perfumes) during the high-risk period
8. Take all prescribed antiemetics as directed, including on Days 2–4, even if feeling well
9. Report nausea and vomiting to the treatment team promptly for timely intervention

Guideline Implementation Considerations

Despite the availability of highly effective antiemetics and well-disseminated guidelines, studies consistently demonstrate a significant gap between guideline recommendations and real-world practice. Closing this gap requires systematic, multi-level implementation strategies.¹¹

Barriers to Guideline-Concordant Antiemetic Prescribing

Strategies for Improving Guideline Concordance

Standardized Antiemetic Order Sets

Computerized physician order entry (CPOE) systems with embedded antiemetic order sets that automatically link to the emetogenic risk of the prescribed chemotherapy regimen are the single most effective implementation strategy. Features should include:

• Automatic emetogenic risk classification based on the ordered chemotherapy regimen
• Pre-populated antiemetic orders with correct agents, doses, and schedules for each risk level
• Inclusion of both Day 1 (pre-chemotherapy) and Days 2–4 (delayed-phase) prescriptions
• Alerts when antiemetic orders are discordant with the emetogenic risk level
• Pharmacist verification step prior to chemotherapy administration

Clinical Decision Support

• Real-time alerts when chemotherapy is ordered without corresponding antiemetic orders
• Risk-stratified antiemetic recommendations displayed at the point of prescribing
• Patient-specific risk factor integration (age, sex, prior CINV history) into recommendations

Nursing-Driven Assessment Protocols

• Standardized CINV assessment at each infusion visit, documented in the electronic health record
• Use of validated tools (NRS, MAT) for consistent quantification of nausea and vomiting
• Nurse-initiated standing orders for breakthrough antiemetics based on assessment results
• Telephone follow-up assessment at 24–48 hours and 72–96 hours post-chemotherapy for the first cycle

Pharmacist-Led Interventions

• Clinical pharmacist review of all chemotherapy orders for antiemetic concordance before dispensing
• Pharmacist-led patient counseling on antiemetic adherence, with emphasis on Days 2–4 medications
• Pharmacist adjustment of antiemetic regimens under collaborative practice agreements

Quality Metrics for CINV Management

Institutional Protocol Development

Every institution administering chemotherapy should maintain a written antiemetic protocol that:

1. Defines emetogenic risk classification for the most commonly used regimens
2. Specifies standard antiemetic regimens for each risk category with exact drug names, doses, routes, and schedules
3. Includes a breakthrough CINV algorithm with agent selection and escalation steps
4. Is reviewed and updated at least annually with reference to the most recent guideline updates
5. Is integrated into the CPOE system as order sets
6. Includes patient education materials in the patient’s preferred language

Patient Education

Effective patient education is a critical component of CINV management. Patients who understand the purpose and schedule of their antiemetic regimen are significantly more likely to adhere to delayed-phase medications.¹²

Key Education Topics

1. Types of nausea and vomiting: Explain that nausea may occur not just on the day of treatment but also on Days 2–5 (delayed CINV), and that preventive medications must be taken even if the patient feels well on Day 1
2. Medication schedule: Provide a written, calendar-format schedule showing the name, dose, route, and time of each antiemetic for Days 1–4 (or longer as appropriate)
3. Side effect management: Discuss expected side effects (sedation from olanzapine — take at bedtime; insomnia from dexamethasone — take in the morning; constipation from 5-HT3 RAs — use bowel regimen)
4. Breakthrough medications: Explain which PRN medications are prescribed, when to take them, and how to differentiate between prophylactic and rescue agents
5. When to contact the care team: Instruct patients to report nausea/vomiting that does not respond to rescue medications, inability to keep down oral medications or fluids, signs of dehydration, or weight loss
6. Dietary guidance: Provide the dietary and lifestyle recommendations outlined above
7. Non-pharmacological strategies: Inform patients of adjunctive strategies (acupressure wristbands, relaxation techniques) and offer resources

Conclusion

Effective CINV prevention and management requires a systematic approach that begins with accurate emetogenic risk classification of the chemotherapy regimen, incorporates patient-specific risk factors, applies evidence-based multi-drug antiemetic prophylaxis, and includes structured assessment and follow-up. The evolution from single-agent antiemetic prophylaxis to the current four-drug regimen for HEC — incorporating NK1 receptor antagonists, 5-HT3 receptor antagonists, dexamethasone, and olanzapine — has substantially improved clinical outcomes. However, the persistent gap between guideline recommendations and clinical practice underscores the need for institutional implementation strategies, standardized order sets, and ongoing quality improvement. With guideline-concordant prophylaxis and proactive management, the majority of patients can now receive emetogenic chemotherapy with minimal nausea and vomiting, preserving quality of life and supporting treatment completion.

References